Signals flagged in the original
Provisional estimate — refines shortly Full breakdown ↓
The White House has refuted claims that President Trump accessed the retatrutide weight-loss drug via the FDA's compassionate use program. The drug, produced by Eli Lilly, is not currently approved by the FDA.
Our neutral summary
The White House has refuted claims that President Trump accessed the retatrutide weight-loss drug via the FDA's compassionate use program. The drug, produced by Eli Lilly, is not currently approved by the FDA.
The reporting belongs to The Hill; we don't reproduce it.
No note attached
on this article.
White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
White House denies report on Trump's access to Eli Lilly obesity drug